Roche subsidiary, Genentech, has announced that the US FDA has accepted its supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery ...

Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.

Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively. ET verified the price with several chemists and ...